Publications by authors named "Roland Jimenez"

Claim this Profile
V
Valbenazine Sprinkle: An Alternative Formulation of Valbenazine for Oral Administration in Patients With Dysphagia.
Nagdeep Giri, Roland Jimenez, Linda Rees, Alexander Mar, Ali Bristow

Clin Transl Sci· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and Pharmacologic Characterization of the Dihydrotetrabenazine Isomers of Deutetrabenazine and Valbenazine.
Satjit Brar, Arjun Vijan, Fiona L Scott, Roland Jimenez, Hui Zhang

Clin Pharmacol Drug Dev· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa.
Peter LeWitt, Grace S Liang, C Warren Olanow, Karl D Kieburtz, Roland Jimenez

Clin Neuropharmacol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A long-term, open-label study of valbenazine for tardive dyskinesia.
Jean-Pierre Lindenmayer, Cherian Verghese, Stephen R Marder, Joshua Burke, Roland Jimenez

CNS Spectr· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia.
Stephen R Marder, Carlos Singer, Jean-Pierre Lindenmayer, Caroline M Tanner, Cynthia L Comella, Roland Jimenez

J Clin Psychopharmacol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.
Stewart A Factor, Gary Remington, Cynthia L Comella, Christoph U Correll, Joshua Burke, Roland Jimenez

J Clin Psychiatry· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials.
Dao Thai-Cuarto, Christopher F O'Brien, Roland Jimenez, Grace S Liang, Joshua Burke

Drug Saf· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects.
Rosa Luo, Haig Bozigian, Roland Jimenez, Gordon Loewen, Christopher F O'Brien

Psychopharmacol Bull· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Robert A Hauser, Stewart A Factor, Stephen R Marder, Mary Ann Knesevich, Paul M Ramirez, Roland Jimenez

Am J Psychiatry· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.
Christopher F O'Brien, Roland Jimenez, Robert A Hauser, Stewart A Factor, Joshua Burke

Mov Disord· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density.
Bruce Carr, W Paul Dmowski, Chris O'Brien, Ping Jiang, Joshua Burke, Roland Jimenez

Reprod Sci· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study.
Michael P Diamond, Bruce Carr, W Paul Dmowski, William Koltun, Chris O'Brien, Roland Jimenez

Reprod Sci· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study.
Bruce Carr, Linda Giudice, W Paul Dmowski, Chris O'Brien, Ping Jiang, Roland Jimenez

J Endometr Pelvic Pain Disord· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.
Markus Walter, Areti Philotheou, François Bonnici, Anette-G Ziegler, Roland Jimenez

Diabetes Care· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
R Scott Struthers, Andrew J Nicholls, John Grundy, Takung Chen, Roland Jimenez

J Clin Endocrinol Metab· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of serum luteinizing hormone in postmenopausal women by an orally administered nonpeptide antagonist of the gonadotropin-releasing hormone receptor (NBI-42902).
R Scott Struthers, TaKung Chen, Bruce Campbell, Roland Jimenez, Henry Pan

J Clin Endocrinol Metab· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis